Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I)

##STR00001##

M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I)

##STR00001##

M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

Disclosed herein are conjugates that include a ligand, and a compound having the structure of formula (I) ##STR00001##
M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

Disclosed herein are conjugates that include a ligand, and a compound having the structure of formula (I) ##STR00001##
M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

A vehicle to carry a powered medication that addresses the limitations of the prior art. It includes a system and method. A powder delivery system includes a first panel and a second panel coupled together around a periphery of the panels to form a sealed void therebetween, each the panel having a width and length about equal to a standard credit card width and length, respectively; and a powder, disposed in the void, having a quantity at least about equal to an active dose of the powder, wherein a thickness of the panels with the powder disposed therebetween is not greater than about 0.1 inches and more preferably not greater than about 0.03 inches.

The present invention discloses a composition and method for treating menstruation related symptoms. The composition comprises an effective amount of a nonsteroidal anti-inflammatory drug (NSAID) comprising at least one of naproxen and ketoprofen. The composition is administrated before an onset of menstruation or during menstruation. The composition is provided in a pharmaceutical package. The package comprises a label indicating a quantity of the formulation to be consumed for a specific time and day in coordination with a menstrual period.

The present invention discloses a composition and method for treating menstruation related symptoms. The composition comprises an effective amount of a nonsteroidal anti-inflammatory drug (NSAID) comprising at least one of naproxen and ketoprofen. The composition is administrated before an onset of menstruation or during menstruation. The composition is provided in a pharmaceutical package. The package comprises a label indicating a quantity of the formulation to be consumed for a specific time and day in coordination with a menstrual period.

Disclosed herein are conjugates that include a ligand, and a compound having the structure of formula (I)

##STR00001##

M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.